Celadon Pharmaceuticals PLC (LSE:CEL) — Market Cap & Net Worth
Market Cap & Net Worth: Celadon Pharmaceuticals PLC (CEL)
Celadon Pharmaceuticals PLC (LSE:CEL) has a market capitalization of $112.25K (GBX922.53 Million) as of June 22, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31255 globally and #1103 in its home market, demonstrating a 11.67% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Celadon Pharmaceuticals PLC's stock price GBX13.40 by its total outstanding shares 68845800 (68.85 Million). Review debt load of Celadon Pharmaceuticals PLC to assess the company's total debt and financial obligations.
Celadon Pharmaceuticals PLC Market Cap History: 2018 to 2025
Celadon Pharmaceuticals PLC's market capitalization history from 2018 to 2025. Data shows change from $829.28K to $112.25K (-26.18% CAGR).
Index Memberships
Celadon Pharmaceuticals PLC is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$937.70 Million | 0.01% | #350 of 722 |
Weight: Celadon Pharmaceuticals PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Celadon Pharmaceuticals PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Celadon Pharmaceuticals PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
12.84x
Celadon Pharmaceuticals PLC's market cap is 12.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.38 Million | $2.00K | -$4.78 Million | 691.06x | N/A |
| 2022 | $423.02K | $24.00K | -$17.41 Million | 17.63x | N/A |
| 2023 | $963.30K | $75.00K | -$7.14 Million | 12.84x | N/A |
Competitor Companies of CEL by Market Capitalization
Companies near Celadon Pharmaceuticals PLC in the global market cap rankings as of June 22, 2026.
Key companies related to Celadon Pharmaceuticals PLC by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #554 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #602 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #554 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #602 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.50 |
Celadon Pharmaceuticals PLC Historical Marketcap From 2018 to 2025
Between 2018 and today, Celadon Pharmaceuticals PLC's market cap moved from $829.28K to $ 112.25K, with a yearly change of -26.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | GBX112.25K | -10.67% |
| 2024 | GBX125.65K | -86.96% |
| 2023 | GBX963.30K | +127.72% |
| 2022 | GBX423.02K | -69.39% |
| 2021 | GBX1.38 Million | -44.07% |
| 2020 | GBX2.47 Million | +197.98% |
| 2019 | GBX829.28K | 0.00% |
| 2018 | GBX829.28K | -- |
End of Day Market Cap According to Different Sources
On Jun 21st, 2026 the market cap of Celadon Pharmaceuticals PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $112.25K USD |
| MoneyControl | $112.25K USD |
| MarketWatch | $112.25K USD |
| marketcap.company | $112.25K USD |
| Reuters | $112.25K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Celadon Pharmaceuticals PLC
Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products. Its products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.